-
EP3287143
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3287143
| EP3287143 - CKAP4-MOLECULAR-TARGETED ANTITUMOR AGENT [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 31.01.2020 Database last updated on 14.06.2024 | |
| Former | Request for examination was made Status updated on 26.01.2018 | ||
| Former | The international publication has been made Status updated on 20.09.2017 | Most recent event Tooltip | 12.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Osaka University 1-1 Yamadaoka Suita-shi, Osaka 565-0871 / JP | [2018/09] | Inventor(s) | 01 /
KIKUCHI, Akira c/o OSAKA UNIVERSITY 1-1 Yamadaoka Suita-shi Osaka 565-0871 / JP | 02 /
FUMOTO, Katsumi c/o OSAKA UNIVERSITY 1-1 Yamadaoka Suita-shi Osaka 565-0871 / JP | 03 /
KIMURA, Hirokazu c/o OSAKA UNIVERSITY 1-1 Yamadaoka Suita-shi Osaka 565-0871 / JP | [2018/09] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2018/09] | Application number, filing date | 16755122.5 | 28.01.2016 | [2018/09] | WO2016JP52485 | Priority number, date | JP20150038343 | 27.02.2015 Original published format: JP 2015038343 | [2018/09] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016136372 | Date: | 01.09.2016 | Language: | JA | [2016/35] | Type: | A1 Application with search report | No.: | EP3287143 | Date: | 28.02.2018 | Language: | EN | [2018/09] | Search report(s) | International search report - published on: | JP | 01.09.2016 | (Supplementary) European search report - dispatched on: | EP | 08.08.2018 | Classification | IPC: | A61K45/00, A61K31/7105, A61K31/713, A61K39/395, A61K48/00, A61K49/00, A61P35/00, A61P35/02, G01N33/15, G01N33/50 | [2018/09] | CPC: |
A61K31/7105 (EP,US);
C07K16/28 (US);
A61K31/713 (EP,US);
A61K39/395 (EP,US);
A61K48/00 (EP,US);
A61K49/00 (EP,US);
A61P1/18 (EP);
A61P11/00 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
C07K16/3023 (US);
C07K16/303 (US);
C12N15/1138 (EP,US);
C12Q1/6886 (EP,US);
G01N33/5011 (EP,US);
G01N33/5023 (EP,US);
G01N33/57423 (EP,US);
G01N33/57438 (EP,US);
G01N33/57488 (US);
G01N33/57492 (US);
C07K2317/76 (US);
C12N2310/14 (EP,US);
C12N2310/531 (EP,US);
C12Q2600/118 (EP,US);
C12Q2600/136 (EP,US);
C12Q2600/158 (EP,US);
C12Q2600/178 (EP,US);
G01N2333/4704 (US);
G01N2333/705 (EP,US);
G01N2500/02 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/09] | Title | German: | CKAP4-MOLEKULAR-GEZIELTES ANTITUMORMITTEL | [2018/09] | English: | CKAP4-MOLECULAR-TARGETED ANTITUMOR AGENT | [2018/09] | French: | AGENT ANTITUMORAL CIBLANT MOLÉCULAIREMENT CKAP4 | [2018/09] | Entry into regional phase | 20.09.2017 | Translation filed | 20.09.2017 | National basic fee paid | 20.09.2017 | Search fee paid | 20.09.2017 | Designation fee(s) paid | 20.09.2017 | Examination fee paid | Examination procedure | 20.06.2016 | Request for preliminary examination filed International Preliminary Examining Authority: JP | 20.09.2017 | Examination requested [2018/09] | 20.09.2017 | Date on which the examining division has become responsible | 25.02.2019 | Amendment by applicant (claims and/or description) | 04.02.2020 | Despatch of a communication from the examining division (Time limit: M04) | 03.04.2020 | Reply to a communication from the examining division | 21.01.2021 | Despatch of a communication from the examining division (Time limit: M04) | 14.05.2021 | Reply to a communication from the examining division | 13.06.2023 | Despatch of a communication from the examining division (Time limit: M04) | 09.10.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 23.01.2018 | Renewal fee patent year 03 | 22.01.2019 | Renewal fee patent year 04 | 21.01.2020 | Renewal fee patent year 05 | 19.01.2021 | Renewal fee patent year 06 | 13.01.2022 | Renewal fee patent year 07 | 13.01.2023 | Renewal fee patent year 08 | 12.01.2024 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2008014484 (UNIV MARYLAND [US], et al) [X] 1,2,4-7 * paragraph [0051]; example 4 *; | [XI]WO2008144485 (UNIV MARYLAND [US], et al) [X] 1-7,15 * examples 3,4 * [I] 8-10; | [X]US2012201810 (NG LIU IRENE OI LIN [CN], et al) [X] 1,4,6,7 * claim 1 *; | [A] - MIN-HONG LI ET AL, "Expression of cytoskeleton-associated protein 4 is related to lymphatic metastasis and indicates prognosis of intrahepatic cholangiocarcinoma patients after surgery resection", CANCER LETTERS, US, (20130901), vol. 337, no. 2, doi:10.1016/j.canlet.2013.05.003, ISSN 0304-3835, pages 248 - 253, XP055440125 [A] 11-15 * abstract;; figure 3 * DOI: http://dx.doi.org/10.1016/j.canlet.2013.05.003 | International search | [XYA]JP2013515505 (CuRNA, Inc.) [X] 1-2, 4-10 * , claims 35 to 36; paragraphs [0025], [0054] & WO 2011/1090741 A2 claims 35 to 36; paragraphs [0025], [0054] & US 2012/0295953 A1 & US 2015/0126587 A1 & EP 2519634 A2 & CA 2785177 A1 & CN 102770540 A & RU 2012124234 A & KR 10-2012-0105023 A * [Y] 3 [A] 14; | [XYA] - LIU Z et al., "Effect of small interfering RNA targeting p63 on the proliferation and invasiveness of human cholangiocarcinoma cells in vitro", J. South. Med. Univ., (20120200), vol. 32, no. 2, ISSN 1673-4254, pages 207 - 210, XP 009505916 [X] 1-2, 4-6, 8-10 * Abstract, Fig. 3 * [Y] 3 [A] 14 | [XYA] - YE, S et al., "p63 regulates growth of esophageal squamous carcinoma cells via the Akt signaling pathway", Int. J. Oncol., (20140600), vol. 44, no. 6, ISSN 1019-6439, pages 2153 - 2159, XP 009505908 [X] 1-2, 4-6, 8-10 * Abstract, page 2157, right column, lines 1 to 5, Figure 1,2 * [Y] 3 [A] 14 | [YA] - CONRADS, TP et al., "CKAP4/p63 Is a Receptor for the Frizzled-8 Protein-related Antiproliferative Factor from Interstitial Cystitis Patients", J. Biol. Chem., vol. 281, no. 49, ISSN 0021-9258, pages 37836 - 37843, XP 055440733 [Y] 3 * Abstract, FIGURE 4,5 * [A] 14 | [YA] - SHI, RY et al., "High Expression of Dickkopf- Related Protein 1 is Related to Lymphatic Metastasis and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma Patients After Surgery", Cancer, vol. 119, no. 5, ISSN 1097-0142, pages 993 - 1003, XP 055482417 [Y] 12 * Abstract, page 997, left column, column of 'DKK1 Was Highly Expressed in ICC Cells and Tissues', Figure 4A * [A] 6, 14 | [YA] - YAMABUKI, T et al., "Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas", Cancer Res., (20070315), vol. 67, no. 6, doi:doi:10.1158/0008-5472.CAN-06-3369, ISSN 0008-5472, pages 2517 - 2525, XP 007915206 [Y] 12 * Abstract, Figure 1 * [A] 6, 14 | [XYA] - LI, MH et al., "Expression of cytoskeleton- associated protein 4 is related to lymphatic metastasis and indicates prognosis of intrahepatic cholangiocarcinoma patients after surgery resection", Cancer Lett., (20130901), vol. 337, no. 2, ISSN 0304-3835, pages 248 - 253, XP 055440125 [X] 11, 13 * ABSTRACT, Fig. 3 * [Y] 12 [A] 14 | [XYA] - BIR, F et al., "Potential utility of p63 expression in differential diagnosis of non- small- cell lung carcinoma and its effect on prognosis of the disease", Med. Sci. Monit., (20140209), vol. 20, ISSN 1643-3750, pages 219 - 226, XP 055482430 [X] 11, 13 * Abstract * [Y] 12 [A] 14 | [XA] - KENGO YANAGITA et al., "Haigan Soshiki Kanja Kessei ni Okeru CKAP4 no Hatsugen Kento", Nippon Byori Gakkai Kaishi, (20110326), vol. 100, no. 1, ISSN 0300-9181, page 381, XP009505913 [X] 15 * , entire text of P1-J10-1 * [A] 14 | [A] - SOLDEVILLA, B et al., "Tumor-derived exsosomes are enriched in deltaNp73, which promotes oncogenic potential in acceptor cells and correlates with patient survival", Hum. Mol. Genet., vol. 23, no. 2, ISSN 0964-6906, pages 467 - 478, XP 055482464 [A] 14 * Abstract * |